Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Efficacy of IV Lignocaine Versus IV Nalbuphine for Attenuation of Pressor Response Diring Laryngoscopy and Intubation in Patients Planned for Thyroid Surgery

ID
Name
ASarwar
Description
Comparison of I/V nalbuphine versus I/V xylocain in attanuation of pressor response during intubation and laryngeoscopy in patients undergoing for thyroid surgery,selection of better supressor agent minimises the drug repated side effects like hypertention tachycardia but also helps in heamodynamically stability at induction.
Trial arms
Trial start
2023-12-30
Estimated PCD
2024-03-01
Trial end
2024-06-01
Status
Not yet recruiting
Phase
Early phase I
Treatment
Lignocaine
Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
Arms:
Lignocain, nalbuphine
Other names:
Nalbuphine
Size
60
Primary endpoint
Reduce stress response during intubation and hemodynamic stabilty
10 minutes
Achieve hemodynamic stabilty and smooth intubation
10 minutes
Eligibility criteria
Inclusion Criteria: * middle age(18_40) * Asa 1 and 2 * Non hypertensive * Thyroid patients * patient who gives consent Exclusion Criteria: * hypertensive * Asa 3 and 4 * Patient refusal
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2023-11-21

1 organization

1 product

1 indication

Organization
Sheikh Zayed Medical College
Product
Lignocaine
Indication
Hemodynamic Stability